Touchlight was awarded Best Emerging UK Biotech Company in 2015 at OBN awards. Touchlight developed an in vitro process to amplify circular DNA templates to commercial scale and quality. It uses two enzymes and rolling circle amplification and their closed-linear constructs, called doggybones or dbDNA. The error rate is low and their system eliminates the need for antibiotic resistance genes.
Touchlight intends for their technology to be used in development and commercialization of DNA products with applications in cell therapy, gene editing, DNA vaccines, DNA monoclonal antibodies and DNA nanotechnology. Touchlight established a GMP (Good Manufacturing Practice) dbDNA production facilty in 2016 and claims their DNA amplification system that meets cGMP (Current Good Manufacturing Practice) standards produces multi-gram scale dbDNA and is more cost effective than for producing plasmids by plasmid fermentation.
Executive Management Lead